Trust Signals
Written by the FormBlends Medical Team. Reviewed 2026-05-29. Claims graded by evidence type in the ledger table below. No affiliate relationships with any peptide vendor discussed on this page. Sources listed at the bottom are real, verifiable references.Key Takeaways
- Peptide Sciences does not list retatrutide in its public catalog as of mid-2026. Absence from the catalog is not guaranteed to be permanent.
- Retatrutide is a 39-amino-acid GLP-1/GIP/glucagon triple agonist still in Phase 3 trials. Its C20 fatty-acid conjugation makes synthesis harder than simpler research peptides.
- In Eli Lilly's Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), the highest-dose group achieved roughly 17.5% mean body weight loss at 24 weeks, the strongest published weight-loss signal in the GLP-1 class at that time.
- Any vendor claiming to sell retatrutide should provide HPLC purity of at least 98% and mass-spec confirmation near 4,474 Da. A COA without both is insufficient for a peptide this structurally complex.
- Buying and self-administering retatrutide outside a clinical trial carries real risks: sequence errors, conjugation failures, endotoxin contamination, and inaccurate fill weight, none of which are visible without lab testing.
Direct Answer: Does Peptide Sciences Sell Retatrutide?
As of mid-2026, Peptide Sciences does not list retatrutide on its public catalog. The compound remains in Phase 3 clinical trials, is not FDA-approved, and its complex 39-amino-acid structure with fatty-acid conjugation makes it more expensive and technically demanding to synthesize than the peptides Peptide Sciences typically carries.Table of Contents
- Why Is Retatrutide Not Listed by Peptide Sciences?
- What Is Retatrutide and How Does It Work?
- Evidence Ledger: What the Research Actually Shows
- Mechanism With Numbers: The Triple Agonist Biology
- What Most Pages Get Wrong About Sourcing Retatrutide
- How to Read a Retatrutide COA: Operational Literacy
- Honest Head-to-Head: Retatrutide vs. Semaglutide vs. Tirzepatide
- Why the Synthesis Complexity Rule Matters: Chemistry Behind the Risk
- Legal and Regulatory Status in 2026
- FAQ
- Sources
Why Is Retatrutide Not Listed by Peptide Sciences?
Peptide Sciences is a US-based research-chemical vendor known for well-characterized peptides: BPC-157, TB-500, CJC-1295, and similar compounds with established synthetic routes and stable research demand. Retatrutide sits outside that profile for several practical reasons.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →First, scale of synthesis complexity. Retatrutide's C20 fatty-acid conjugation requires post-SPPS (solid-phase peptide synthesis) chemistry that adds cost, time, and failure points compared to unconjugated peptides. Most research-chemical vendors do not run the specialized conjugation chemistry in-house.
Second, regulatory attention. GLP-1 class peptides, especially newer ones like retatrutide, draw more regulatory scrutiny than older research peptides. Vendors serving an academic research market have commercial reasons to avoid products that attract enforcement interest before they have broad legitimate research use.
Third, no approved reference standard exists yet. Because retatrutide is not FDA-approved, there is no pharmacopeial reference standard against which a vendor could independently verify their synthesis. This increases the risk of selling a misidentified product and exposes vendors to liability.
What Is Retatrutide and How Does It Work?
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly and Company. It is the first published clinical-stage triple agonist targeting three receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR).
GLP-1R agonism drives the insulin-secretion and appetite-suppression effects familiar from semaglutide. GIPR agonism, the mechanism tirzepatide adds to GLP-1R agonism, further potentiates insulin secretion and may reduce nausea. Adding glucagon receptor agonism is the key structural difference: glucagon increases hepatic glucose output and energy expenditure, which is why the glucagon component carries theoretical fat-oxidation benefits beyond what dual agonists produce.
The compound carries a C20 fatty-acid side chain that extends its half-life, enabling once-weekly subcutaneous dosing in trials. Eli Lilly's published Phase 2 data used doses ranging from 0.5 mg to 12 mg weekly.
Evidence Ledger: What the Research Actually Shows
| Claim | Best Evidence Type | Effect Direction | Confidence | Key Caveat |
|---|---|---|---|---|
| Retatrutide produces substantial weight loss in adults with obesity | Phase 2 RCT (Jastreboff et al., NEJM 2023, n=338) | Positive, large effect at highest dose | Moderate | Single Phase 2 trial; Phase 3 data pending |
| Triple agonism produces greater weight loss than GLP-1 alone | Mechanistic reasoning plus Phase 2 indirect comparison | Directionally positive vs. historical GLP-1 data | Low | No head-to-head RCT vs. semaglutide or tirzepatide yet |
| Glucagon receptor agonism increases energy expenditure | Animal studies and human mechanistic studies | Positive in animals; modest in humans | Low to Moderate | Glucagon agonism also raises blood glucose; net effect depends on GLP-1 co-agonism |
| Once-weekly dosing is feasible via fatty-acid conjugation extending half-life | Phase 2 PK data (Jastreboff et al., 2023) | Confirmed in trial design | High (mechanism established in this class) | PK from research-chemical vendors' product is not validated |
| GI side effects (nausea, vomiting) are the primary tolerability concern | Phase 2 RCT safety data | Consistent with GLP-1 class | Moderate | Severity at high doses may exceed tirzepatide based on Phase 2 dropout rates |
| Research-chemical retatrutide matches Lilly's compound | No published verification studies | Unknown | Very Low | No third-party batch analysis of vendor products is publicly available |
Mechanism With Numbers: The Triple Agonist Biology
The key Phase 2 result (Jastreboff et al., NEJM 2023) enrolled 338 adults with a BMI of 30 or greater, without diabetes, in a 24-week randomized double-blind placebo-controlled trial across dose groups. The 12 mg weekly cohort achieved approximately 17.5% mean body weight reduction. Placebo produced roughly 1.6% reduction. The trial used dose escalation over the first 16 weeks before hitting the maintenance dose, consistent with other GLP-1 class protocols.
For comparison: in the STEP 1 trial (Wilding et al., NEJM 2021, n=1,961), semaglutide 2.4 mg weekly produced approximately 14.9% mean body weight loss at 68 weeks. Tirzepatide at 15 mg in the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022, n=2,539) produced approximately 20.9% at 72 weeks. Retatrutide's 24-week result approaching tirzepatide's 72-week result is notable, but a longer Phase 2 arm (48 weeks in a substudy) and Phase 3 data are needed before this signal is confirmed.
What the mechanism does NOT prove: superior cardiometabolic outcomes. Weight loss magnitude has not proven to be a reliable proxy for cardiovascular event reduction in this drug class. The SURPASS-CVOT and SELECT trials showed cardiovascular benefit for tirzepatide and semaglutide respectively, but no cardiovascular outcomes trial has been completed for retatrutide.
What Most Pages Get Wrong About Sourcing Retatrutide
The commodity framing treats "does a vendor carry it" as the primary question. The harder question is whether any vendor-produced retatrutide is actually retatrutide.
Retatrutide's synthesis has three categories of failure that simple peptides do not share:
Conjugation failure. The C20 fatty-acid chain (a C20 diacid linked via a linker to a lysine side chain) is added in a post-SPPS step. If the conjugation is incomplete or the fatty acid is attached at the wrong position, the product may have a similar mass but completely different pharmacokinetics, potentially no half-life extension and no meaningful activity in vivo. HPLC alone may not catch this; mass-spec fragmentation analysis or nuclear magnetic resonance is needed.
Sequence truncation. Synthesizing 39 amino acids in sequence on solid phase generates incomplete fragments at each coupling step. Without aggressive purification, a batch can contain 5 to 15% truncated sequences that HPLC purity may overstate if the analysis conditions are not set for full resolution of all fragments.
Endotoxin contamination. Bacterial lipopolysaccharides (endotoxins) are a byproduct of any synthesis process using biological reagents or non-aseptic handling. A subcutaneously injected compound with high endotoxin content causes local inflammation and potentially systemic fever response. The US Pharmacopeia limit for parenteral peptides is 5 EU/kg body weight per hour, which translates to less than 1 EU/mg for most dosing scenarios. A COA that omits endotoxin testing is a meaningful red flag.
How to Read a Retatrutide COA: Operational Literacy
| Test | What It Confirms | Minimum Acceptable Result | What It Cannot Confirm |
|---|---|---|---|
| HPLC purity | Relative abundance of the main peak vs. impurities | Greater than or equal to 98% | Whether the main peak is actually retatrutide vs. a related peptide |
| Mass spectrometry (ESI-MS or MALDI-TOF) | Molecular weight match to expected ~4,474 Da | Within 1 Da of expected MW | Stereochemistry, linker attachment position, conjugation completeness |
| Endotoxin (LAL test) | Bacterial contamination level | Less than 1 EU/mg | Viral or fungal contaminants |
| Water content (Karl Fischer or TGA) | True peptide content vs. water weight | Less than 10% moisture | Residual organic solvents |
| Residual solvents | Acetonitrile, TFA, DMF traces from synthesis | Within ICH Q3C limits | Novel synthesis byproducts not in the solvent screen |
Reconstitution note: retatrutide is typically supplied as a lyophilized powder. Reconstitute with bacteriostatic water (0.9% benzyl alcohol preserved), not plain sterile water, to extend post-reconstitution stability. A common starting dilution in research protocols is 1 mg/mL, but always confirm fill weight by mass before calculating dose. Vials labelled as "5 mg" can vary in actual peptide content if moisture is not accounted for.
Honest Head-to-Head: Retatrutide vs. Approved Alternatives
| Factor | Retatrutide (research chemical) | Semaglutide 2.4 mg (Wegovy, FDA-approved) | Tirzepatide 15 mg (Zepbound, FDA-approved) |
|---|---|---|---|
| Weight loss evidence quality | Phase 2 only (n=338, 24 weeks) | Phase 3 RCT, CVOT data (STEP 1, SELECT) | Phase 3 RCT, ongoing CVOT (SURMOUNT-1) |
| Approximate peak weight loss in trials | ~17.5% at 24 weeks (Phase 2, highest dose) | ~14.9% at 68 weeks (STEP 1) | ~20.9% at 72 weeks (SURMOUNT-1) |
| Regulatory status | Phase 3 trials; not approved | FDA-approved for obesity (June 2021) | FDA-approved for obesity (Nov 2023) |
| Product identity certainty | Unverifiable without independent lab testing | Pharmaceutical grade, pharmacopeial standards | Pharmaceutical grade, pharmacopeial standards |
| Cardiovascular outcomes data | None | SELECT trial: 20% reduction in MACE | SURPASS-CVOT positive; full results pending wide publication |
| Cost and access | Lower nominal cost from research vendors; insurance does not cover | High list price; insurance coverage variable | High list price; insurance coverage variable |
| Where retatrutide loses | Evidence base, identity certainty, safety monitoring, legal clarity | Approved agents win on every quality-and-safety dimension | |
Why Synthesis Complexity Is the Risk: Chemistry Behind the Rule
The rule "complex peptides require better COA scrutiny" has a specific chemical basis worth understanding.
In solid-phase peptide synthesis, each amino acid coupling step carries an efficiency of roughly 95 to 99.5% depending on the resin, reagents, and conditions. For a 39-amino-acid sequence, even at 99% per-step efficiency, the theoretical yield of perfect full-length sequence is 0.99 to the power of 38, which is roughly 68%. At 98% per-step efficiency it falls to roughly 46%. This means a substantial fraction of any synthesis run consists of truncated or deleted sequences. Purification by HPLC removes most of these, but aggressive purity claims require gradient optimization specifically designed to resolve all 39-residue fragments from the full-length product.
The fatty-acid conjugation step adds another variable. The C20 diacid is typically attached via an NHS-ester or HATU-mediated coupling at a specific lysine epsilon-amine. If the protecting group strategy is imperfect, conjugation can occur at other lysine residues or at the N-terminus, producing a compound with the correct molecular formula but incorrect pharmacophore geometry. Mass spectrometry confirms the mass but not the position. This is not a hypothetical concern: it is a documented issue in the development of fatty-acid conjugated peptides broadly.
Stability after reconstitution: fatty-acid conjugation does improve resistance to proteolytic degradation compared to unconjugated peptides, because the fatty acid sterically hinders some protease binding sites. However, this applies to in vivo stability, not to chemical degradation during storage. Peptide bonds in aqueous solution are susceptible to hydrolysis, and cysteine (if present in the sequence) undergoes oxidation. Proper storage at 2 to 8 degrees Celsius and minimal freeze-thaw cycles remain important regardless of conjugation chemistry.
Legal and Regulatory Status in 2026
Retatrutide has no FDA approval, no IND exemption for general research use, and no compounding-pharmacy pathway that applies in the way some other GLP-1 peptides (semaglutide, tirzepatide) have been compounded under shortage designations. The shortage-based compounding pathway that opened for semaglutide and tirzepatide was specific to those named drugs appearing on the FDA drug shortage list. Retatrutide has never been on that list because it is not an approved drug.
Research-chemical vendors operate under the general principle that selling compounds for genuine in-vitro or animal research, labelled not for human consumption, is not explicitly prohibited by the Controlled Substances Act for peptides not specifically scheduled. However, this does not mean such sales are consequence-free. The FDA has broad authority under the Federal Food, Drug, and Cosmetic Act to act against unapproved drugs promoted for human use, and enforcement has occurred in the GLP-1 analogue space.
Outside the US, the picture varies substantially. Many jurisdictions classify any injectable peptide sold for human use as a prescription medicine, making purchase and possession without a prescription an offense regardless of the research-chemical label.
FAQ
Does Peptide Sciences sell retatrutide?
As of mid-2026, Peptide Sciences does not list retatrutide on its public catalog. The company focuses on well-characterized research peptides and has not added retatrutide, which remains in Phase 3 clinical trials and is not FDA-approved or commercially manufactured at scale.
What is retatrutide and why is it hard to source?
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly. Its 39-amino-acid structure with C20 fatty-acid conjugation makes it harder and more expensive to synthesize than simpler peptides like BPC-157, which is why few vendors carry it reliably.
Is retatrutide legal to buy as a research chemical?
Retatrutide is not FDA-approved for any indication. In the United States it occupies a grey area: selling it "not for human consumption" for genuine laboratory research is not explicitly prohibited, but human administration outside a clinical trial is not sanctioned. The regulatory picture varies by country.
How do research-chemical vendors synthesize retatrutide?
Vendors use solid-phase peptide synthesis followed by fatty-acid conjugation to replicate the C20 side chain. The multi-step synthesis introduces multiple failure points. Without validated HPLC and mass spectrometry COA data, purity claims cannot be verified.
What should a COA for retatrutide show?
A credible COA should show HPLC purity of 98% or greater, a mass-spec confirmation matching the molecular weight of approximately 4,474 Da, an endotoxin result below 1 EU/mg, and a moisture or residual-solvent result. Any COA missing mass-spec data is insufficient for a peptide this complex.
How does retatrutide compare to semaglutide for weight loss?
In Eli Lilly's Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), retatrutide at the highest dose produced roughly 17.5% mean body weight loss at 24 weeks, compared to approximately 15% for semaglutide 2.4 mg at 68 weeks in the STEP 1 trial. Direct head-to-head RCT data do not yet exist.
What are the main risks of buying retatrutide from an unregulated vendor?
Key risks include incorrect peptide sequence or truncated fragments, fatty-acid conjugation errors rendering the compound inactive, high endotoxin levels causing inflammatory reactions, and incorrect dosing due to inaccurate fill weight. None of these failures are detectable without laboratory analysis.
Why is retatrutide harder to synthesize than tirzepatide or semaglutide?
Retatrutide is a 39-amino-acid peptide with a specific C20 fatty-acid conjugation site. Longer chains and fatty-acid conjugation require more synthesis steps, more purification cycles, and more points of potential error than the shorter GLP-1 agonist peptides like semaglutide (31 amino acids) or even tirzepatide (39 amino acids but with a different conjugation chemistry).
Will Peptide Sciences or similar vendors likely add retatrutide in the future?
If retatrutide receives FDA approval, research-chemical vendors often begin listing analogues shortly afterward. Whether the compound they sell matches the approved drug's structure and quality is a separate question that requires independent verification of each batch.
How should I store reconstituted retatrutide if I obtain it?
Fatty-acid conjugated peptides are generally more stable than unconjugated peptides, but lyophilized powder should still be stored at 2 to 8 degrees Celsius and protected from light. After reconstitution with bacteriostatic water, use within a timeframe consistent with your vendor's stability data, typically within a few weeks when refrigerated.
What is the current clinical trial status of retatrutide?
As of 2026, retatrutide is in Phase 3 trials for obesity and type 2 diabetes under Eli Lilly's program. The Phase 2 results published in NEJM in 2023 showed significant weight reduction. Phase 3 completion and any regulatory submission timeline are subject to Lilly's announcements.
Sources
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. PMID 37366315.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002. PMID 33567185.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216. PMID 35658024.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232. PMID 37952131.
- US Food and Drug Administration. Compounding and the Drug Supply Chain: Shortage Determinations. FDA.gov. Accessed 2026.
- International Council for Harmonisation. ICH Q3C: Impurities: Guideline for Residual Solvents. ICH.org.
- US Pharmacopeia. General Chapter 85: Bacterial Endotoxins Test. USP-NF.
- Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015;20(1):122-128. PMID 25450038.